CD28/B7 regulation of autoimmune diabetes

Immunologic Research

Volumn 16, Issue 1, 1997, Pages 71-84

  Herold, Kevan C ^a   Lenschow, Deborah J ^b   Bluestone, Jeffrey A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

Autoimmune diabetes; B7; CD28; Costimulation; NOD mouse; Streptozotocin; Tolerance

Indexed keywords

AUTOANTIGEN; B7 ANTIGEN; CD28 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; GENETIC SUSCEPTIBILITY; IMMUNOREGULATION; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; T LYMPHOCYTE ACTIVATION;

EID: 0030933453     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02786324     Document Type: Article

References (78)

1. Eisenbarth GS: Type 1 diabetes mellitus: a chronic autoimmune disease. N Engl J Med 1986;314: 1360-1367.
2. Atkinson MA, Maclaren N: The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994;331: 1428-1436.
3. Rossini AA, Mordes JP, Like AA: Immunology of insulin dependent diabetes mellitus. Ann Rev Immunol 1985;3:289-320.
4. Castano L, Eisenbarth GS: Type-1 diabetes: a chronic autoimmune disease of human, mouse and rat. Ann Rev Immunol 1990;6: 647-679.
5. Jenkins MK: The ups and downs of T cell costimulation. Immunity 1994; 1 :443-446.
6. Lafferty KJ, Gill RG: The maintenance of self-tolerance Immunol Cell Biol 1993;71:209-214.
7. Harlan DM, Hengartner H, Huang ML, Kang YH, Ave R, Moreadity RW, Pircher H, Gray GS, Ohashi PS, Freeman GJ, Nadler LM, June CH, Aichele P: Proc Natl Acad Sci USA 1994;91:3137-3141.
8. Ohashi PS, Oehen S, Buerki K, Pircher H, Ohashi CT, Odermatt B, Malissen B, Zinkernagel RM, Hengartner H: Ablation of tolerance and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991;65: 305-317.
9. Miller J, Daitch L, Rath P, Selsing E: Tissue specific expression of allogeneic class II molecules induces neither islet rejection nor clonal inactivation of alloreactive T cells. J Immunol 1990;144:334-341.
10. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional clonal inactivation: a costimulatory pathway determines the outcome of T cell receptor occupancy. Ann Rev Immunol 1989;7:445-480.
11. Linsley PS, Ledbetter JA: The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol 1993;11:191-212.
12. June CH, Ledbetter JA, Linsley PS, Thompson CB: Role of the CD28 receptor in T-cell activation. Immunol Today 1990;11: 211-216.
13. Handing RA, McArthur JG, Gross JA, Raulet DH, Allison JP: CD28-mediated signalling costimulates murine T cells and prevents induction of energy in T-cell clones. Nature 1992;356:607-609.
14. Green JM, Noel PJ, Sperling AI, Walunas TL, Gray GS, Bluestone JA, Thompson CB: Absence of B7-dependent responses in CD28-deficient mice. Immunity 1994;1: 501-508.
15. Yokochi T, Holly RD, Clark EA: B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol 1992;128: 823-827.
16. Azuma M, Ito D, Yagita H, Okumura K, Philips JH, Lanier LL, Somoza C: B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993;366:76-79.
17. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VA Jr, Lombard LA, Gray GS, Nadler LM: Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993;262:909-911.
18. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173:721-730.
19. Freeman GH, Borriello F, Hodes RJ, Reiser H, Gribben JG, Ng JW, Kim J, Goldberg JM, Hathcock K, Laszlo G, Lombard LA, Wang S, Gray GS, Nadler LM, Sharpe AH: Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med 1993; 178:2185-2192.
20. Hathcock KS, Laszlo G, Pucillo C, Linsley P, Hodes RJ: Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J Exp Med 1994;180: 631-640.
21. Lenschow DJ, Su GH-T, Zuckerman LA, Nabavi N, Jellis CL, Gray, GS, Miller S, Bluestone, JA: Expression and functional significance of an additional ligand for CTLA-4. Proc Natl Acad Sci USA 1993;90:11,054-11,058.
22. Lenschow DJ, Walunas TL, Bluestone JA: CD28/B7 system of T cell costimulation. Ann Rev Immunol 1996;14:233-258.
23. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174: 561-573.
24. Walunas TL, Lenschow DJ, Balcker CY, Linsley PS, Greeman GJ, Green JM, Thompson CB, Bluestone JA: CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
25. Krumrnel MF, Allison JP: CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells. J Exp Med 1996;183:2533-2540.
26. Walunas TL, Bakker CY, Bluestone JA: CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-2550.
27. Karandikar NJ, Vanderlugt CL, Walunas TL, Miller SD, Bluestone JA: CTLA-4: a negative regulator of autoimmune disease. J Exp Med 1996; 184:783-788.
28. Leach DR, Krummel MF, Allison JP: Enhancement of antitumor immunity by CTLA4 blockade. Science 1996;271:1734-1736.
29. Lenschow DJ, Zeng Y, Thistlethwaite JR, Montag A, Brady W, Gibson MG, Linsley PS, Bluestone JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992;257:789-792.
30. Lin H, Bolling SF, Linsley PS, Wei R, Gordon D, Thompson CB, Turka LA: Long-term acceptance of major histocompatibility complex mix-matched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J Exp Med 1993;178:1801-1806.
31. Harlan DM, Barnett MA, Abe R, Pechhold K, Patterson MB, Gray GS, June CH: Very-low-dose streptozotocin induces diabetes in insulin promoter-mB7-1 transgenic mice. Diabetes 1995;44:816-823.
32. Guerder S, Meyerhoff J, Flavell R: The role of T cell costimulatory B7-1 in autoimmunity and the induction and maintenance of tolerance to peripheral antigens. Immunity 1994;1:155-166.
33. Wong S, Guerder S, Visintin I, Reich E-P, Swenson KI, Flavell RA, Janeway CA Jr: Expression of the costimulatory molecule B7-1 in pancreatic beta cells accelerates diabetes in the NOD mouse. Diabetes 1995;44:326-329.
34. Makino S, Kunimoto K, Muraoka Y, Mizushimi Y, Katagiri K, Tochino Y: Breeding of a non-obese diabetic strain of mice. Exp Anim 1980;26:1-8.
35. Miller BJ, Appel MC, O'Neil JJ, Wicker LS: Both the Lyt-2+ and L3T4+ T cell subsets are required for the transfer of diabetes in non-obese diabetic (NOD) mice. J Immunol 1988;140:52-62.
36. Shehadeh NN, LaRosa R, Lafferty KJ: Altered cytokine activity in adjuvant inhibition of autoimmune diabetes. J Autoimmun 1993;6:291-297.
37. Katz JD, Benoist C, Mathis D: T helper cell subsets in insulin-dependent diabetes. Science 1995; 268:1185-1188.
38. Kaufman DL, Clare-Salzler M, Tian J, Forsthumber T, Ting GSP, Robinson P, Atkinson MA, Sercarz EE, Tobin AJ, Lehmann PV: Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993;366:69-72.
39. Tisch R, Yang X-D, Singer SM, Liblau RS, Fugger L, McDevitt HO: Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993;366:72-75.
40. Akashi T, Nagafuchi S, Anzai K, Kondo S, Kitamura D, Ono J, Watanabe T, Niho Y: Suppression of insulitis and diabetes in B lymphocyte deficient NOD mice. Diabetes 1996;45(Suppl 2):82A.
41. Lenschow DJ, Ho SC, Sattar H, Rhee L, Gray G, Nabavi N, Herold KC, Bluestone JA: Differential effects of anti-B7-1 and anti-B7-2 mAb treatment on the development of diabetes in the NOD mouse. J Exp Med 1995; 181:1145-1155.
42. Shizuru J, Taylor-Edwards C, Banks BA, Gregory AK, Fathman CG: Immunotherapy of the non-obese diabetic mouse: treatment with an antibody to T-helper lymphocytes. Science 1988;240:659-662.
43. Hasegawa Y, Yokono K, Taki T, Amano K, Tominga Y, Yoreda R, Yagi N, Maeda S, Yagita H, Okymura K, Kasuga M.: Prevention of autoimmune insulin-dependent diabetes in non-obese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int Immunol 1994; 6:831-838.
44. Herold KC, Vezys V, Gage A, Montag A: Prevention of autoimmune diabetes by treatment with anti-LFA-1 and anti-ICAM-1 monoclonal antibodies. Cell Immunol 1994;157:489-500.
45. Zeng Y, Gage A, Montag A, Rothlein R, Thistlethwaite JR, Bluestone JA: Inhibition of transplant rejection by pretreatment of xenogeneic pancreatic islet cells with anti-ICAM-1 antibodies. Transplantation 1994;58:681-689.
46. Baron JL, Reich EP, Visintin I, Janeway CA Jr.: The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between alpha 4-integrins and vascular cell adhesion molecule-1. J Clin Invest 1994;93:1700-1708.
47. Lenschow D, Herold KC, Rhee L, Patel B, Koons A, Qin H-Y, Fuchs E, Singh B, Thompson CB, Bluestone JA: CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996;5:285-293.
48. Yang XD, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD, McDevitt HO: Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoirnmunity and the diabetogenic process. J Exp Med 1994;180:995-1004.
49. Pennline KH, Roque-Gaffrey E, Monahan M: Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clin Immunol Immunopath 1994; 71:169-175.
50. Wogensen L, Lee M-S, Sarvetnick N: Production of interleukin 10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 1994;179:1379-1384.
51. Kawai K, Shihinian A, Mak TW, Ohashi PS: Skin allograft rejection in CD28-deficient mice. Transplantation 1996;61:352-355.
52. Shahinian A, Pfeffer K, Lee KP, Kindry TM, Kishihara K, Wakeham A, Kawai K, Ohashi PS, Thompson CB, Mak TW: Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993;261:609-612.
53. Kundig TM, Shahinian A, Kawai K, Mittrucker H-W, Sebzda E, Bachmann MF, Mak T, Ohashi PS: Duration of TCR stimulation determines costimulatory requirements of T cells. Immunity 1996; 5:39-50.
54. Bluestone JA: New perspectives of CD28-B7-mediated T cell costimulation. Immunity 1995;2: 555-559.
55. Van der Pouw-Kraan T, De Jong R, Aarden L: Development of human Th1 and Th2 cytokine responses: the cytokine production profile of T cells is dictated by the primary in vitro stimulus. Eur J Immunol 1993;23:1-5.
56. Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Mabavi N, Glimcher LH: B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: Application to autoimmune disease therapy. Cell 1995;80: 707-718.
57. Like AA, Rossini AA: Streptozotocin-induced pancreatic insulitis. New model of diabetes mellitus. Science 1976;193:415-418.
58. Kolb H: IDDM: Lessons for the low-dose streptozotocin model in mice. Diabetes Reviews 1993;1: 116-126.
59. Herold KC, Montag AG, Fitch FW: Treatment with anti-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozotocin. Diabetes 1987;36:796-801.
60. Wiede LG, Lacy PE: Low-dose streptozotocin-induced autoimmune diabetes in islet transplant model. Diabetes 1991;40:1157-1163.
61. Herold KC, Montag AG, Buckingham F: Induction of tolerance to autoimmune diabetes with islet antigens. J Exp Med 1992;176: 1107-1114.
62. Herold KC, Vezys V, Koons A, Lenschow D, Thompson C, Bluestone JA. CD28/B7 costimulation regulates autoimmune diabetes induced with multiple low doses of streptozotocin. J Immunol, in press.
63. Herold KC, Vezys V, Sun Q, Viktora D, Seung E, Reiner S, Brown D: Regulation of cytokine production during development of autoimmune diabetes induced with multiple lowdoses of streptozotocin. J Immunol 1996;156:3521-527.
64. Cockfield SM, Ramassar V, Urmson J, Halloran PF: Multiple low-dose streptozotocin-induced systemic MHC expression in mice by triggering T cells to release IFN-γ. J Immunol 1989;142:1120-1128.
65. Baumann EE, Buckingham F, Herold KC: Intrathymic transplantation of islet antigen affects CD8+ diabetogenic T-cells resulting in tolerance to autoimmune IDDM. Diabetes 1995;44:871-877.
66. Haskins K, McDuffie M: Acceleration of diabetes in young NOD mice with a CD4+ islet-specific T cell clone. Science 1990;249:1433-1436.
67. Peterson JD, Haskins K: Transfer of diabetes in the NOD-scid mouse by CD4 T-cell clones. Differential requirements for CD8 T-cells. Diabetes 1996;45:326-336.
68. McKnight AJ, Perez VL, Shea CM, Gray GS, Abbas AK: Costimulatory dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice. J Immunol 1994; 52:5220-5225.
69. Webb L, Feldmann M: Critical role of CD28/B7 costimulation in the development of human Th2 cells. Blood 1995; 86:3479-3486.
70. Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ: Identification of an alternate CTLA-4 ligand costimulatory for T cell activation. Science 1993; 262:905-907.
71. Ueda Y, Levine BL, Huang ML, Greeman GJ, Nadler LM, June CH, Ward SG: Both CD28 ligands CD80 (B7-1) and CD86 (B7-2) activate phosphatidylinositol 3-kinase, and wortmannin reveals heterogeneity in the regulation of T cell IL-2 secretion. Immunol 1995;7:957-966.
72. Levine BL, Ueda Y, Craighead N, Huang ML, June CH: CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro. Int Immunol 1995;7:891-904.
73. Freeman GJ, Boussiotis VA, Anamanthan A, Bernstein GM, Ke X-Y, Rennert PC, Gray GS, Gribben JG, Nadler LM: B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of 1L-4. Immunity 1995;2:523-532.
74. Seder RA, Germain RN, Linsley PS, Paul WE: CD28-mediated costimulation of interleukin-2 (IL-2) production plays a critical role in T cell priming for IL-4 and interferon gamma production. J Exp Med 1994;179:299-304.
75. Miller SD, Vanderglut CL, Lenschow DJ, Pope JG, Karandikar NJ, Dal Canto MC, Bluestone JA: Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 1995; 3:739-745.
76. Windhagen A, Newcombe J, Dansond F, Strand C, Woodroofe MN, Cuzrer MC, Hafler DA: Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J Exp Med 1995;182:1985-1996.
77. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe A: Loss of CTLA4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-547.
78. Waterhouse P, Penninger JM, Timms E, Wakeham A, Shahinian A, Lee KP, Thompson CB, Grieger H, Mak T: Lymphoproliferative disorders with early lethality in mice deficient in CTLA4. Science 1995;270:985-988.